valve

stent-liberador-drogas-sirolimus-everolimus

Thin vs. Ultrathin Stents: 1-Year Clinical Results After IVUS/OCT-Guided Implantation

Second generation drug-eluting stents have lower frequency of thrombotic complications and in-stent restenosis. While clinical results have significantly improved, having a 2-3% annual rate of these complications within the first year after angioplasty is still worrisome. This resulted in the development of stents with struts &lt;70 µm (ultrathin), with bioresorbable polymer and abluminal cover. Stents<a href="https://solaci.org/en/2022/07/20/thin-vs-ultrathin-stents-1-year-clinical-results-after-ivus-oct-guided-implantation/" title="Read more" >...</a>

Pacientes que no siguen nuestro consejo y sorpresivamente tienen menos eventos

Angioplasty in Nonagenarians Is Increasingly Frequent: How Does It Evolve?

Currently, the number of nonagenarian patients undergoing angioplasty (whether elective, urgent or emergency) has increased.&nbsp; This population is linked to more comorbidities and has barely been included in most randomized studies or registries. As such, we do not have robust evidence on this group. Researchers conducted an analysis of the J-PCI OUTCOME Registry, in which<a href="https://solaci.org/en/2022/07/19/angioplasty-in-nonagenarians-is-increasingly-frequent-how-does-it-evolve/" title="Read more" >...</a>

¡Gracias a todos por ser parte de las Jornadas SOLACI Paraguay 2022!

Thanks everyone for making part of Paraguay SOLACI Sessions 2022!

We have reached the end of SOLACI Sessions 44th edition.&nbsp; We have enjoyed 2 days of intense scientific activities with multiple educational symposia, case study discussions, theoretical and practical approaches to issues of interest in interventional cardiology and fruitful knowledge exchange between prestigious colleagues from Paraguay and Latin America.&nbsp; With over 200 registered attendees and<a href="https://solaci.org/en/2022/07/04/thanks-everyone-for-making-part-of-paraguay-solaci-sessions-2022/" title="Read more" >...</a>

El Grupo MIL realizó 4 TAVIS en Paraguay

The Latin American Group of Interventionist Women Performed 4 TAVR Cases in Paraguay

The MIL-SOLACI continues to grow and keeps developing activities to foster integration and women’s participation all across Latin America.&nbsp; IN this opportunity, and for the first time, the area directed by Dr. Carla Agatiello (ARG) performed 4 transcatheter aortic valve implantations (TAVR) at the National University’s Clinical Hospital of Asunción, in Paraguay.&nbsp; The interventions, performed<a href="https://solaci.org/en/2022/06/30/the-latin-american-group-of-interventionist-women-performed-3-tavr-cases-in-paraguay/" title="Read more" >...</a>

La enfermedad vascular periférica se asocia a más eventos en el TAVI

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving<a href="https://solaci.org/en/2022/06/09/tavr-more-information-supports-its-use/" title="Read more" >...</a>

Un guiño para la trombólisis guiada por Catéter en tromboembolismo pulmonar

A Nod to Catheter-Guided Thrombolysis in Pulmonary Thromboembolism

Pulmonary thromboembolism (PTE) is the third most frequent cardiovascular disease, with an increasing prevalence over time. The stratification of these patients is paramount to decide their therapeutic approach, since there have been high mortality rates for certain subgroups. The European Society of Cardiology, in its latest guidelines (2019), classified the severity of PTE according to<a href="https://solaci.org/en/2022/06/07/a-nod-to-catheter-guided-thrombolysis-in-pulmonary-thromboembolism/" title="Read more" >...</a>

Experiencia de la cirugía

New-Generation ACURATE Neo2

Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce<a href="https://solaci.org/en/2022/06/03/new-generation-acurate-neo2/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

MitraClip Reduces Renal Function Deterioration

Severe mitral regurgitation is associated to cardiac failure and hospitalization and over time is accompanied by kidney failure, which leads to higher mortality.&nbsp; In the COAPT study, in patients with low ejection fraction, MitraClip showed benefits over medical treatment, but there was an important group of people with kidney function deterioration.&nbsp; The evolution and benefit<a href="https://solaci.org/en/2022/06/01/mitraclip-reduces-renal-function-deterioration/" title="Read more" >...</a>

acceso_transcaval

TAVR: If Not Transfemoral, We Should Consider Transcaval Access

Transcatheter aortic valve replacement (TAVR) through transfemoral access has already proven its great benefits, but this access cannot be used in certain patients, and alternative accesses need to be considered for such cases. One of the most commonly used accesses is the transaxillary or transubclavian access (AX), which, however, is associated with more complications (especially<a href="https://solaci.org/en/2022/06/01/tavr-if-not-transfemoral-we-should-consider-transcaval-access/" title="Read more" >...</a>

EuroPCR 2022

EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results.&nbsp; The aim of this multicenter, prospective study was to assess the safety and efficacy of the<a href="https://solaci.org/en/2022/05/30/europcr-2022-clasp-tr-study-promising-results-of-endovascular-intervention-of-tricuspid-regurgitation/" title="Read more" >...</a>

Top